Product
Surufatinib plus Toripalimab
1 clinical trial
1 indication
Indication
Neuroendocrine CarcinomaClinical trial
A Phase 3, Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Surufatinib Plus Toripalimab Versus FOLFIRI as a Secondline Treatment in Patients With Advanced Neuroendocrine CarcinomaStatus: Recruiting, Estimated PCD: 2025-05-31